Vector Development
Reovirus sigma 1 fiber in adenovirus enhances infectivity
Published in Vaccine Weekly, October 19th, 2005
According to recent research from the United States, "Adenovirus serotype 5 (Ad5) has been used for gene therapy with limited success because of insufficient infectivity in cells with low expression of the primary receptor, the coxsackie and adenovirus receptor (CAR). To enhance infectivity in tissues with low CAR expression, tropism expansion is required via non-CAR pathways."
"Serotype 3 Dearing reovirus utilizes a fiber-like sigma 1 protein to infect cells expressing sialic acid and junction adhesion molecule 1 (JAM 1)," said Yuko...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-10-19)
More Articles from Vaccine Weekly
- Ascaris Vaccine Development
Ascaris suum antigen protects against Ascaris lung infection - Drug Development
Monoclonal antibody combination neutralizes natural rabies virus variants - Leukemia Vaccine Development
Dendritic cell vaccine shows promise for chronic lymphocytic leukemia - Measles-Mumps-Rubella-Varicella Vaccine
Dose response of children to measles, mumps, rubella and varicella vaccine tested - Metapneumovirus Vaccine Development
Cotton rat is model of human metapneumovirus infection and immunity - Allergy Medicine
T cells induced by Foxp3-retrovirus infection control contact allergy - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
